1. Cost effectiveness of long-acting risperidone: What can pharmacoeconomic models teach us?

   • Lieven Annemans

   Introduction 17 September 2012 Pages: 1 - 2

2. Pharmacoeconomics of long-acting risperidone: Results and validity of cost-effectiveness models

   • Alan Haycox

   Review Article 17 September 2012 Pages: 3 - 16

   

3. Modelling the treated course of schizophrenia: Development of a discrete event simulation model

   • Bart M. S. Heeg
   • Erik Buskens
   • Ben A. van Hout

   Original Research Article 17 September 2012 Pages: 17 - 33

   

4. Long-acting risperidone compared with oral olanzapine and haloperidol depot in schizophrenia: a Belgian cost-effectiveness analysis

   • Diana De Graeve
   • Ann Smet
   • Joseph Peuskens

   Original Research Article 17 September 2012 Pages: 35 - 47

   

5. Costs and effects of long-acting risperidone compared with oral atypical and conventional depot formulations in Germany

   • Gerd Laux
   • Bart M. S. Heeg
   • Angelika Mehnert

   Original Research Article 17 September 2012 Pages: 49 - 61

   

6. Modelling the impact of compliance on the costs and effects of long-acting risperidone in Canada

   • P. S. Chue
   • Bart M. S. Heeg
   • Ben A. van Hout

   Original Research Article 17 September 2012 Pages: 62 - 74

   

7. Cost effectiveness of long-acting risperidone injection versus alternative antipsychotic agents in patients with schizophrenia in the USA

   • Natalie Christine Edwards
   • Julie C. Locklear
   • Ronald J. Diamond

   Original Research Article 17 September 2012 Pages: 75 - 89